HSCS Nasdaq Finance Services Financials FY2022βFY2026
HeartSciences Inc. had $0.0M of revenue in fiscal 2026, down 2.3% on the year before.
Last close Β· Oct 23, 2026
$3.14
0.9%Hi! I read HeartSciences Inc.βs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
β2.3%
No. Sales fell 2.3% last year.
Does it make a profit?
β212,602.3%
No. It lost money last year.
Does profit turn into cash?
β172,797.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days HeartSciences Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
December 14, 2026
Monday Β· in 49 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Sep 14, 2026 | Q1 '27 | After the market closes | 10-Q β |
| Jul 23, 2026 | Q4 '26 | After the market closes | 10-K β |
| Mar 16, 2026 | Q3 '26 | After the market closes | 8-K β |
| Dec 15, 2025 | Q2 '26 | After the market closes | 8-K β |
| Sep 11, 2025 | Q1 '26 | After the market closes | 8-K β |
| Jul 24, 2025 | Q4 '25 | After the market closes | 8-K β |
| Mar 13, 2025 | Q3 '25 | After the market closes | 8-K β |
| Dec 16, 2024 | Q2 '25 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· HeartSciences Inc. had $0.0M of revenue in fiscal 2026, down 2.3% on the year before. Its operating margin was β195,648.8%, down 5,817.0Β pts: of every 100 in sales, about β195,649 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· HeartSciences Inc. lost $9.1M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$7.4M in fiscal 2026, β172,797.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably HeartSciences Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.9M | $1.7M | $5.8M | $1.1M | $1.7M |
| Interest coverage | β12.7x | β25.1x | β17.8x | β16.7x | β11.2x |
| Current ratio | 0.6x | 1.5x | 4.2x | 0.6x | 0.5x |
| Quick ratio | 0.4x | 1.1x | 3.8x | 0.4x | 0.4x |
| Total assets | $2.1M | $3.3M | $9.5M | $4.2M | $5.3M |
| Total liabilities | $8.1M | $3.1M | $2.2M | $4.0M | $5.0M |
| Shareholders' equity | β$6.1M | $0.2M | $7.3M | $0.2M | $0.2M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· HeartSciences Inc. passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | 5 / 8 | 5 / 8 | 1 / 8 | 3 / 7 |
| Accruals ratio | β56.7% | β21.6% | β8.4% | β19.7% | β36.2% |
| Altman Z'' | β105.64 | β70.95 | β20.19 | β74.39 | β66.36 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Gross profit | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Research and development | $3.0M | $2.5M | $2.9M | $4.4M | $2.8M |
| Operating income | β$4.7M | β$6.1M | β$6.3M | β$8.4M | β$8.4M |
| Interest expense | $0.4M | $0.2M | $0.4M | $0.5M | $0.8M |
| Income tax | β | β | β | $0.0M | $0.0M |
| Net income | β$4.8M | β$6.4M | β$6.6M | β$8.8M | β$9.1M |
| Diluted EPS | β$1.45 | β$80.00 | β$18.74 | β$9.34 | β |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | β |
| Cash flow | |||||
| Cash from operations | β$3.6M | β$5.8M | β$6.1M | β$7.4M | β$7.4M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M |
| Free cash flow | β$3.6M | β$5.8M | β$6.1M | β$7.4M | β$7.4M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.1M | $0.2M | $0.4M | $0.2M | $1.3M |
| Balance sheet | |||||
| Cash and short-term investments | $0.9M | $1.7M | $5.8M | $1.1M | $1.7M |
| Current assets | $1.9M | $2.7M | $7.4M | $2.2M | $2.6M |
| Current liabilities | $3.5M | $1.8M | $1.8M | $3.7M | $4.9M |
| Inventory | $0.7M | $0.7M | $0.6M | $0.7M | $0.7M |
| Property and equipment, net | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M |
| Intangible assets | β | β | $1.6M | $1.6M | $1.7M |
| Total assets | $2.1M | $3.3M | $9.5M | $4.2M | $5.3M |
| Total liabilities | $8.1M | $3.1M | $2.2M | $4.0M | $5.0M |
| Preferred stock | $0.0M | $0.0M | β | β | β |
| Shareholders' equity | β$6.1M | $0.2M | $7.3M | $0.2M | $0.2M |
| Margins | |||||
| Gross margin | 45.1% | 46.2% | 67.2% | 56.8% | 60.5% |
| Operating margin | β32,704.2% | β117,557.7% | β33,902.2% | β189,831.8% | β195,648.8% |
| EBITDA margin | β32,519.4% | β117,040.4% | β33,752.2% | β188,977.3% | β195,002.3% |
| Net margin | β33,529.9% | β122,198.1% | β35,511.8% | β199,209.1% | β212,602.3% |
| FCF margin | β25,319.4% | β111,382.7% | β32,982.3% | β168,550.0% | β172,797.7% |
| Returns | |||||
| Return on capital employed | 341.0% | β420.3% | β81.4% | β1,607.2% | β2,094.8% |
| Return on equity | β | β | β175.0% | β233.0% | β4,239.2% |
| Return on assets | β231.1% | β236.4% | β103.3% | β127.7% | β192.8% |
| Return on tangible equity | β | β2,755.6% | β115.3% | β | β |
| Growth | |||||
| Revenue growth | β | β63.9% | 257.7% | β76.3% | β2.3% |
| Share count change | β | β97.6% | 343.4% | 166.2% | β |
| Financial health | |||||
| Interest coverage | β12.7x | β25.1x | β17.8x | β16.7x | β11.2x |
| Current ratio | 0.6x | 1.5x | 4.2x | 0.6x | 0.5x |
| Quick ratio | 0.4x | 1.1x | 3.8x | 0.4x | 0.4x |
| Capital allocation | |||||
| Capex / revenue | 13.2% | 351.9% | 346.8% | 72.7% | 83.7% |
| Stock comp / revenue | 475.0% | 4,775.0% | 2,177.4% | 5,679.5% | 30,520.9% |
| Quality scores | |||||
| Piotroski F-score | β | 5.0 | 5.0 | 1.0 | 3.0 |
| Altman Z'' | β105.6 | β70.9 | β20.2 | β74.4 | β66.4 |
| Accruals ratio | β56.7% | β21.6% | β8.4% | β19.7% | β36.2% |
Source: SEC EDGAR XBRL filings (CIK 0001468492). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
